title: Irbesartan attenuates Ang II-induced BMP-2 expression in human umbilical vein endothelial cells.
abstract: Bone morphogenetic protein-2 (BMP-2), a transforming growth factor-beta superfamily member cytokine, plays a key role both in vascular development and in pathophysiological processes. However, the effects and mechanisms of angiotensin II (Ang II) on BMP-2 expression remain unknown in human umbilical vein endothelial cells (HUVECs). Here we show that Ang II treatment significantly increased BMP-2 expression, associated with NF-kappaB activation, which was suppressed by treatment with pyrrolidine dithiocarbamate (PDTC) or irbesartan. Furthermore, the increased levels of MDA (malondialdehyde) in conditioned media and the decrease in activities of total superoxide dismutases (SOD) caused by Ang II were reversed by irbesartan or PDTC treatment. Our findings indicate that Ang II-induced BMP-2 expression might contribute to NF-kappaB activation. BMP-2 expression induced by Ang II might involve excessive oxidative stress.
authors.affiliation: Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Zhang
authors.forename: Sheng-hua
authors.initials: SH
authors.lastname: Zhou
authors.forename: Shui-Ping
authors.initials: SP
authors.lastname: Zhao
authors.forename: Qi-ming
authors.initials: QM
authors.lastname: Liu
authors.forename: Xu-ping
authors.initials: XP
authors.lastname: Li
authors.forename: Xiang-Qian
authors.initials: XQ
authors.lastname: Shen
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D055396:Bone Morphogenetic Protein 2 / Q000235:genetics* / Q000378:metabolism; D002478:Cells, Cultured; D003470:Culture Media; D004347:Drug Interactions; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D000077405:Irbesartan; D008315:Malondialdehyde / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology*; D051996:Transcription Factor RelA / Q000378:metabolism; D014471:Umbilical Veins / Q000166:cytology; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; C525718:BMP2 protein, human; D001713:Biphenyl Compounds; D055396:Bone Morphogenetic Protein 2; D003470:Culture Media; D013777:Tetrazoles; D051996:Transcription Factor RelA; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D008315:Malondialdehyde; D013482:Superoxide Dismutase; D000077405:Irbesartan